UNSPSC 51282115: Oximonam

This classification denotes a beta-lactam antibiotic with the molecular formula C12H15N5O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 482M43SL0K, chemically known as acetic acid, ((3-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-methyl-4-oxo-1-azetidinyl)oxy)-, (2s-(2alpha,3beta(z)))- but generally known as oximonam, which bears US NIH Compound Identifier 9571070. European Medicines Agency schedules Oximonam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09531MIG.

UNSPSC 51282115 Oximonam, a Commodity code, covers pharmaceutical products that state and local governments procure for emergency response, community health, and pharmacy benefit programs—including naloxone, generic pharmaceuticals, over-the-counter products, and specialized medical supplies for first-responder use. Recent solicitations show health departments and fire rescue divisions buying naloxone and drug deactivation systems for overdose response, cities acquiring medical and first aid supplies for emergency personnel, and state pharmacy programs sourcing generic multi-source pharmaceuticals and OTC products through cooperative purchasing. Issuing bodies span county health departments, municipal fire departments, state health and human services agencies, and multistate cooperative purchasing alliances; Florida's Seminole County and Minnesota's MMCAP appear as recent active buyers in this space.

The code sees activity across Florida, Texas, and Minnesota in the most recent opportunities. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, designated for quarterly deliveries to its Community Health Building. The City of Tampa released IFB 26P00145 on March 25, 2026, for 169 line items of medical and first aid supplies (estimated at $700,000) for the Tampa Fire Department Rescue Division, with an SLBE set-aside and a 5 percent bid discount for certified small local business enterprises, response due March 13, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to inform future formal solicitation strategy.